SRPT Deadline: Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

News > Business News

Audio By Carbonatix

11:06 AM on Friday, August 15

The Associated Press

NEW YORK--(BUSINESS WIRE)--Aug 15, 2025--

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025. Sarepta is a commercial-stage biopharmaceutical company.

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.

The Allegations: Rosen Law Firm is Investigating the Allegations that Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Misled Investors Regarding its Business Operations.

According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (3) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (4) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against Sarepta Therapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 25, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250815520914/en/

CONTACT: Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]